Additional file 2: of The BRCA1ness signature is associated significantly with response to PARP inhibitor treatment versus control in the I-SPY 2 randomized neoadjuvant setting
Tesa Severson
Denise Wolf
Christina Yau
Justine Peeters
Diederik Wehkam
Philip Schouten
Suet-Feung Chin
Ian Majewski
Magali Michaut
Astrid Bosma
Bernard Pereira
Tycho Bismeijer
Lodewyk Wessels
Carlos Caldas
RenĂŠ Bernards
Iris Simon
Annuska Glas
Sabine Linn
Laura van ât Veer
10.6084/m9.figshare.c.3866536_D2.v1
https://springernature.figshare.com/articles/dataset/Additional_file_2_of_The_BRCA1ness_signature_is_associated_significantly_with_response_to_PARP_inhibitor_treatment_versus_control_in_the_I-SPY_2_randomized_neoadjuvant_setting/5357005
I-SPY 2 Trial participating sites and institutional review boards (IRB). (XLSX 48 kb)
2017-08-25 05:00:00
Breast cancer
Neoadjuvant
BRCAness
PARP inhibition
Triple-negative breast cancer